Esperion Therapeutics Inc.

Led by Roger Newton, PhD, the former head of the atherosclerotic research team at Warner-Lambert's Parke-Davis division that discovered and developed {Lipitor}, Esperion Therapeutics Inc. was founded to exploit the reverse cholesterol transport pathway for the development of a new class of anti-cholesterol drugs, starting with a preclinical candidate licensed from Pharmacia & Upjohn Inc. called ApoA-I Milano.